Cancer Chemotherapy and Pharmacology

, Volume 30, Issue 1, pp 31–36 | Cite as

Studies on the mechanism of the synergistic interaction between 2′-deoxy-5-azacytidine and cisplatin

  • James L. Abbruzzese
  • Philip Frost
Original Articles Synergistic Interaction, 2′-Deoxy-5-Azacytidine, Cisplatin


2′-Deoxy-5-azacytidine (5-aza-CdR) and cisplatin interact to produce synergistic cytotoxicity against many human tumor cell lines. Preliminary experiments designed to explore the mechanism of this synergy suggested a poor correlation between synergy and the degree of genomic hypomethylation measured following exposure to 5-aza-CdR. Subsequent studies using plasmid DNA suggested that rather than DNA hypomethylation, incorporation of 5-aza-CdR into DNA mediated increased cisplatin binding to DNA and could therefore be essential to the synergistic interaction between these two agents. In this series of experiments, we evaluated the degree of synergy with cisplatin produced against two human melanoma cell lines by two additional antimetabolites that were chosen on the basis of their biochemical properties. In addition, we investigated the synergy between 5-aza-CdR and cisplatin in parental and 5-aza-CdR-resistant murine cell lines, which differed in their sensitivity to 5-aza-CdR and DNA methylation status but incorporated similar amounts of 5-aza-CdR into DNA when exposed to this antimetabolite. In the studies testing additional antimetabolites, cytosine arabinoside, which is incorporated into DNA but does not hypomethylate it, produced synergy with cisplatin that was similar or superior to that obtained using 5-aza-CdR. With 3-deaza-adenosine, which is not incorporated into DNA but produces DNA hypomethylation through inhibition of S-adenosylhomocysteine hydrolase, a primarily antagonistic interaction was observed in the two cell lines studied. In the 5-aza-CdR-sensitive and-resistant cell lines, a very similar synergistic interaction was documented for 5-aza-CdR and cisplatin despite the significant difference observed in DNA methylation levels. Taken as a whole, these data suggest that DNA hypomethylation was not critical to the synergistic cytotoxicity produced by 5-aza-CdR and cisplatin. This finding suggests additional strategies that could further modulate this interaction.


Methylation Level Synergistic Interaction Human Melanoma Cell Arabinoside Human Tumor Cell Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aggarwal BB, Eessalu TE, Hass PE (1985) Characterization of receptors for human tumor necrosis factor and their regulation by interferon. Nature 318: 665Google Scholar
  2. 2.
    Albino AP, Lloyd KO, Houghton AN, Oettgen HF, Old FJ (1981) Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. J Exp Med 154: 1764Google Scholar
  3. 3.
    Benz C, DeGregorio M, Saks S, Sambol N, Holleran W, Ignoffo R, Lewis B, Cadman E (1985) Sequential infusions of methotrexate and 5-fluorouracil in advanced cancer: pharmacology, toxicity, and response. Cancer Res 45: 3354Google Scholar
  4. 4.
    Bergerat JP, Drewinko B, Corry P, Barlogie B, Ho DH (1981) Synergistic lethal effect ofcis-dichlorodiammineplatinum and 1-β-d-arabinofuranosylcytosine. Cancer Res 41: 25Google Scholar
  5. 5.
    Chou J, Chou T-C (1987) Dose effect analysis with microcomputers. Elsevier-Biosoft, Cambridge, United KingdomGoogle Scholar
  6. 6.
    Chou T-C (1977) On the determination of availability of ligand binding sites in steady state systems. J Theor Biol 65: 345Google Scholar
  7. 7.
    Chou T-C, Talalay P (1983) Analyses of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 4: 450Google Scholar
  8. 8.
    Chou T-C, Talalay P (1984) Quantitative analysis of dose effect relationships: the combined effects of multiple drugs on enzyme inhibitors. Adv Enzyme Regul 22: 27Google Scholar
  9. 9.
    Cory JG (1988) Ribonucleotide reductase as a chemotherapeutic target. Adv Enzyme Regul 27: 437Google Scholar
  10. 10.
    Creusot F, Acs G, Christman JK (1982) Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J Biol Chem 257: 2041Google Scholar
  11. 11.
    Djurhuus R, Svardal AM, Veland PM (1989) Differential effects on growth, homocysteine, and related compounds of two inhibitors of S-adenosylhomocysteine catabolism, 3-deazaadenosine, and 3-deazaaristeromycin in C3H/10T1/2 cells. Cancer Res 49: 324Google Scholar
  12. 12.
    Flatau E, Bogenmann E, Jones PA (1983) Variable 5-methylcytosine levels in human tumor cell lines and fresh pediatric tumor explants. Cancer Res 43: 4901Google Scholar
  13. 13.
    Flatau E, Gonzales FA, Michalowsky LA, Jones PA (1984) DNA methylation in 5-aza-2′-deoxycytidine-resistant variants of C3H 10T1/2 C18 cells. Mol Cell Biol 4: 2098Google Scholar
  14. 14.
    Fram RJ, Robichaud N, Bishov SD, Wilson JM (1987) Interactions ofcis-diamminedichloroplatinum (II) with 1-β-d-arabinofuranosylcytosine in LoVo colon carcinoma cells. Cancer Res 47: 3360Google Scholar
  15. 15.
    Frost P, Abbruzzese JL, Hunt B, Lee D, Ellis M (1990) Synergistic cytotoxicity usign 2′-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells. Cancer Res 50: 4572Google Scholar
  16. 16.
    Grem JL, Allegra CJ (1990) Enhancement of the toxicity and DNA incorporation of arabinosyl-5-azacytosine and 1-β-d-arabinofuranosylcytosine by cyclopentenyl cytosine. Cancer Res 50: 7279Google Scholar
  17. 17.
    Jones PA, Taylor SM (1980) Cellular differentiation, cytidine analogs, and DNA methylation. Cell 20: 85Google Scholar
  18. 18.
    Kozolowski JM, Hart IR, Fidler IJ, Hanna N (1984) A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mice. J Natl Cancer Inst 72: 913Google Scholar
  19. 19.
    Liteplo RG (1988) DNA (cytosine) methylation in murine and human tumor cell lines treated with S-adenosylhomocysteine hydrolase inhibitors. Cancer Lett 39: 319Google Scholar
  20. 20.
    McGhee JD, Ginder GD (1979) Specific methylation sites in the vicinity of the chicken B-globin genes. Nature 280: 419Google Scholar
  21. 21.
    Michalowsky LA, Jones PA (1987) Differential nuclear protein binding to 5-azacytosine-containing DNA as a potential mechanism for 5-aza-2′-deoxycytidine resistance. Mol Cell Biol 7: 3076Google Scholar
  22. 22.
    Momparler RL, Derse D (1979) Kinetics of phosphorylation of 5-aza-2′-deoxycytidine by deoxycytidine kinase. Biochem Pharmacol 28: 1443Google Scholar
  23. 23.
    Nyce J (1989) Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res 49: 5829Google Scholar
  24. 24.
    Razin A, Riggs AD (1980) DNA methylation and gene function. Science 210: 604Google Scholar
  25. 25.
    Schiller JH, Bittner G, Storer B, Willson JKV (1987) Synergistic antitumor effects of tumor neerosis factor and γ-interferon on human colon carcinoma cell lines. Cancer Res 47: 2809Google Scholar
  26. 26.
    Vadi H, Drewinko B (1986) Kinetics and mechanism of the 1-β-d-arabinofuranosylcytosine-induced potentiation ofcis-diamminedichloroplatinum(II) cytotoxicity. Cancer Res 46: 1105Google Scholar
  27. 27.
    Veselý J, Čihák A (1977) Incorporation of a potent antileukemic agent 5-aza-2′-deoxycytidine into DNA of cells from leukemic mice. Cancer Res 37: 3684Google Scholar
  28. 28.
    Wadler SW, Schwartz EL, Goldman M, Lyver A, Rader M, Zimmerman M, Itri L, Weinberg V, Wiernik PH (1989) Fluorouracil and recombinant alpha-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 7: 1769Google Scholar
  29. 29.
    Wilson VL, Jones PA, Momparler RL (1983) Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2′-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res 43: 3493Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • James L. Abbruzzese
    • 1
  • Philip Frost
    • 1
    • 2
  1. 1.Department of Medical OncologyThe University of Texas M. D. Anderson Cancer CenterHoustonUSA
  2. 2.Department of Cell BiologyThe University of Texas M. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations